{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:51:54Z","timestamp":1772121114931,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.jhep.2013.03.004","type":"journal-article","created":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T19:31:02Z","timestamp":1363289462000},"page":"153-159","source":"Crossref","is-referenced-by-count":72,"title":["Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial"],"prefix":"10.1016","volume":"59","author":[{"given":"Melissa","family":"Chrispijn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom J.G.","family":"Gevers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen C.","family":"Hol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Monshouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heleen M.","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost P.H.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2013.03.004_b0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1478-3231.2010.02247.x","article-title":"Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases","volume":"31","author":"van Keimpema","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2013.03.004_b0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.molmed.2004.11.004","article-title":"Polycystic liver disease is a disorder of cotranslational protein processing","volume":"11","author":"Drenth","year":"2005","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jhep.2013.03.004_b0015","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2013.03.004_b0020","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/hep.24036","article-title":"Medical and surgical treatment options for polycystic liver disease","volume":"52","author":"Drenth","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.03.004_b0025","doi-asserted-by":"crossref","first-page":"C1205","DOI":"10.1152\/ajpcell.00313.2002","article-title":"Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes","volume":"284","author":"Gong","year":"2003","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jhep.2013.03.004_b0030","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2353\/ajpath.2008.080125","article-title":"Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease","volume":"173","author":"Banales","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2013.03.004_b0035","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hep.22636","article-title":"The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD)","volume":"49","author":"Banales","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.03.004_b0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0168-8278(00)80377-3","article-title":"Regulation and deregulation of cholangiocyte proliferation","volume":"33","author":"Alvaro","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.03.004_b0045","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032,5\u2032-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.03.004_b0050","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.03.004_b0055","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2013.03.004_b0060","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide","volume":"5","author":"Caroli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2013.03.004_b0065","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MOG.0b013e328343433f","article-title":"Somatostatin analogues for treatment of polycystic liver disease","volume":"27","author":"Gevers","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jhep.2013.03.004_b0070","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jhep.2013.03.004_b0075","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2013.03.004_b0080","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","article-title":"Sirolimus reduces polycystic liver volume in ADPKD patients","volume":"19","author":"Qian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2013.03.004_b0085","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.03.004_b0090","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.03.004_b0095","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/1745-6215-12-246","article-title":"Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial","volume":"12","author":"Chrispijn","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.jhep.2013.03.004_b0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jnci\/djr511","article-title":"Targeted therapies for renal cell carcinoma: review of adverse event management strategies","volume":"104","author":"Eisen","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2013.03.004_b0105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2013.03.004_b0110","first-page":"513025","article-title":"Absence of mTOR inhibitor effect on hepatic cyst growth: a case report of a kidney transplant recipient with autosomal dominant polycystic kidney disease","volume":"2012","author":"Friedrich","year":"2012","journal-title":"Case Rep Transplant"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813001530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813001530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T23:01:05Z","timestamp":1539817265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827813001530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0168827813001530"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2013.03.004","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717995518.793474227","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}